Pancreatic Cancer Research

ResearcherUniversity of UtahActive in the last 2 years

Courtney L. Scaife

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2497-4961; OpenAlex author ID A5053671455, A5158644948. Sources: OpenAlex.

Their work

Papers
26 (first author 1, last author 9)
Trials
0
Grants
0
Labs led
1
Collaborators
82
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 3 papers · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 2 papers · 2018: 4 papers · 2019: 4 papers · 2020: 1 paper · 2021: 3 papers · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 26

  1. Pancreatic Adenocarcinoma, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology. Co-author DOI 10.6004/jnccn.2026.0046↗
  2. Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations … Co-author DOI 10.1158/1078-0432.ccr-22-3724↗
  3. Multianalyte Serum Biomarker Panel for Early Detection of Pancreatic Adenocarcinoma. Co-author DOI 10.1200/cci.22.00160↗
  4. Patient Perceptions of Decision-making and Quality-of-life Following Surgical Resection of Pancreatic Adenocarcinoma: A Mixed-methods Study. Co-author DOI 10.1097/as9.0000000000000214↗
  5. Detection of circulating tumor DNA without a tumor-informed search using next-generation sequencing is a prognostic biomarker in pancreatic ductal adenocarcino… Co-author DOI 10.1016/j.neo.2021.06.005↗
  6. Decompositions of the Contribution of Treatment Disparities to Survival Disparities in Stage I-II Pancreatic Adenocarcinoma. First author DOI 10.1245/s10434-020-09267-y↗
  7. Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2021.0017↗
  8. County-level Variation in Use of Surgery and Cancer-specific Survival for Stage I-II Pancreatic Adenocarcinoma. Last author DOI 10.1097/sla.0000000000003236↗
  9. Lymph Node Ratio in Pancreatic Adenocarcinoma After Preoperative Chemotherapy vs. Preoperative Chemoradiation and Its Utility in Decisions About Postoperative … Last author DOI 10.1007/s11605-018-3953-0↗
  10. Disparities in utilization of treatment for clinical stage I-II pancreatic adenocarcinoma by area socioeconomic status and race/ethnicity. Last author DOI 10.1016/j.surg.2018.10.035↗
  11. Hospital-level Variation in Utilization of Surgery for Clinical Stage I-II Pancreatic Adenocarcinoma. Last author DOI 10.1097/sla.0000000000002404↗
  12. Pancreatic Adenocarcinoma, Version 1.2019. Co-author DOI 10.6004/jnccn.2019.0014↗
  13. Causes of Death and Conditional Survival Estimates of Medium- and Long-term Survivors of Pancreatic Adenocarcinoma. Last author DOI 10.1001/jamaoncol.2018.2442↗
  14. Association of time-to-surgery with outcomes in clinical stage I-II pancreatic adenocarcinoma treated with upfront surgery. Last author DOI 10.1016/j.surg.2017.10.054↗
  15. Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins. Co-author DOI 10.1136/esmoopen-2017-000282↗
  16. Advances in surgery for pancreatic cancer. Last author DOI 10.21037/jgo.2018.05.05↗
  17. Implications of inaccurate clinical nodal staging in pancreatic adenocarcinoma. Co-author DOI 10.1016/j.surg.2016.12.029↗
  18. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2017.0131↗
  19. Biomarkers in pancreatic adenocarcinoma: current perspectives. Co-author DOI 10.2147/ott.s100510↗
  20. Initial Misdiagnosis of Proximal Pancreatic Adenocarcinoma Is Associated with Delay in Diagnosis and Advanced Stage at Presentation. Last author DOI 10.1007/s11605-015-2923-z↗
  21. Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer. Co-author DOI 10.1111/hpb.12199↗
  22. Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarkers for pancreatic adenocarcinoma. Co-author DOI 10.1097/mpa.0b013e31825e354d↗
  23. Focused ultrasound-mediated drug delivery to pancreatic cancer in a mouse model. Co-author DOI 10.1186/2050-5736-1-11↗
  24. The clinical utility of CA 19-9 in pancreatic adenocarcinoma: diagnostic and prognostic updates. Co-author DOI 10.2174/1566524011313030003↗
  25. Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, an… Co-author DOI 10.1007/s12029-011-9251-7↗
  26. Genexol inhibits primary tumour growth and metastases in gemcitabine-resistant pancreatic ductal adenocarcinoma. Last author DOI 10.1111/j.1477-2574.2010.00249.x↗

Closest collaborators

The 25 strongest of 82 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sean J. Mulvihill · 15 shared papers, 2012–2023 · strength 1.31
  2. Douglas S. Swords · 10 shared papers, 2015–2021 · strength 1.16
  3. Matthew A. Firpo · 12 shared papers, 2013–2023 · strength 1.09
  4. Ignacio Garrido‐Laguna · 5 shared papers, 2018–2023 · strength 0.61
  5. Josh M. Bleicher · 3 shared papers, 2018–2023 · strength 0.46
  6. Kajsa E. Affolter · 3 shared papers, 2021–2023 · strength 0.42
  7. Andrew H. Ko · 4 shared papers, 2017–2026 · strength 0.38
  8. Brian G. Czito · 4 shared papers, 2017–2026 · strength 0.38
  9. Noelle K. LoConte · 4 shared papers, 2017–2026 · strength 0.38
  10. Robert A. Wolff · 4 shared papers, 2017–2026 · strength 0.38
  11. Eric K. Nakakura · 4 shared papers, 2017–2026 · strength 0.38
  12. Mokenge Peter Malafa · 4 shared papers, 2017–2026 · strength 0.38
  13. Jeffrey M. Hardacre · 4 shared papers, 2017–2026 · strength 0.38
  14. Brian Matthew Wolpin · 4 shared papers, 2017–2026 · strength 0.38
  15. Dana Backlund Cardin · 4 shared papers, 2017–2026 · strength 0.38
  16. Mary E. Dillhoff · 4 shared papers, 2017–2026 · strength 0.38
  17. Andrew M. Lowy · 4 shared papers, 2017–2026 · strength 0.38
  18. Vincent M. Chung · 4 shared papers, 2017–2026 · strength 0.38
  19. Al B. Benson · 4 shared papers, 2017–2026 · strength 0.38
  20. Elena Gabriela Chiorean · 4 shared papers, 2017–2026 · strength 0.38
  21. Christos K Fountzilas · 3 shared papers, 2019–2026 · strength 0.33
  22. Amol Kumar Narang · 3 shared papers, 2019–2026 · strength 0.33
  23. Timothy R. Donahue · 2 shared papers, 2021–2026 · strength 0.27
  24. Charles M. Vollmer · 2 shared papers, 2021–2026 · strength 0.27
  25. Marsha Reyngold · 2 shared papers, 2021–2026 · strength 0.27

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.